Press Release

Number	Title	Date
27	ReGenTree Announces the Results of the ARISE-2 Trial With RGN-259 for the Treatment of Dry Eye: Significant Efficacies Were Con	2017-10-31
26	RegeneRx JV Presents Results of Phase 2b/3 (ARISE-1) Dry Eye Trial at ARVO 2017	2017-05-09
25	RegeneRx Licensee Receives FDA Permission to Conduct a Phase 3 Trial of RGN-137 for Epidermolysis Bullosa in U.S.	2017-02-27
24	RegeneRx Announces First Patients Enrolled in Phase 3 U.S. Dry Eye Clinical Trial (ARISE-2 Trial) with RGN-259	2016-11-09
23	RegeneRx Joint Venture to Begin Second Phase 3 Study Of RGN-259 for Dry Eye Syndrome in 3rd Quarter	2016-08-24
22	RGN-259 Confirms Efficacy in Signs and Symptoms of Dry Eye	2016-05-06
21	RegeneRx and ReGenTree Expand License for Dry Eye	2016-04-28
20	OKLAHOMA BRIEFS(Glioblastoma drug trials planned)	2016-02-17
19	GtreeBNT Acquires New Drug for the Treatment of Glioblastomas	2016-02-15
18	G-treeBNT announces resignation of co-CEO	2016-02-12
17	RegeneRx Announces Completion of Patient Enrollment In Phase 2b/3 U.S. Dry Eye Trial	2016-01-29
16	RegeneRx U.S. Joint Venture, ReGenTree, Launches Web Site	2016-01-28
15	RegeneRx Joint Venture Posts Results of Severe Dry Eye Trial On ClinicalTrials.gov	2015-12-23
14	RegeneRx Updates on U.S. Ophthalmic Clinical Trials	2015-10-21
13	RegeneRx Announces First Patient Enrolled in Phase 3 U.S. Neurotrophic Keratopathy (NK) Clinical Trial with RGN-259	2015-09-21